Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Breast cancer prevention

STAR trial (Study of tamoxifen and raloxifene), which was completed in 2006, demonstrated additional utility of raloxifene in the prevention and treatment of breast cancer. In fact, the absence of associated uterotrophic effects with raloxifene suggests that it may be a safer agent than tamoxifen for use as a chemopreventative in high-risk postmenopausal women [3] therefore, raloxifene has very recently become a new option for breast cancer prevention now available for physicians and their patients. [Pg.1116]

Discuss available options for breast cancer prevention. [Pg.1303]

In the Breast Cancer Prevention Trial (Fisher et al. 1998) a clinical survey aimed at determining the potential of tamoxifen for breast cancer prevention in women at increased risk, 13,338 pre- or postmenopausal women were monitored over 5 years. After randomization, women in the treatment group (n = 6681) were given a 20-mg daily dose of tamoxifen, while the remaining (n = 6707) received a placebo. Although the overall rate of fractures was about the same in both groups, tamoxifen-treated women sustained fewer hip, spine, and Colles fractures. Nevertheless, relevant data may have been biased, since in this trial there was an indiscriminate inclusion of pre- and postmenopausal women and no spinal radiographs were carried out. [Pg.200]

The effects of tamoxifen in women with and without CHD have been analyzed in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial (BCPT). This randomized, placebo-controlled study included 13,388 women at increased risk for breast cancer. The conclusions of the trial are somewhat limited by the fact that it was designed to investigate the effect of tamoxifen as a chemopreventive for breast cancer, and not its effect on CVD risk. There was no indication that tamoxifen would modify the risk of CHD in women with or without heart disease (Reis et al. 2001). [Pg.234]

The most relevant study is the Breast Cancer Prevention Trial (BCPT, NSABP-P1) (Fisher et al. 1998). Initiated in the USA by the National Surgical Adjuvant Breast and Bowel Project, this study recruited 13,388 women considered at high risk for breast cancer based on Gail s probability algorithm (Gail et al. 1989). [Pg.259]

Cuzick J (2005) Aromatase inhibitors for breast cancer prevention. J Clin Oncol 23 1636-1643... [Pg.276]

Cuzick J, Powles T, Veronesi U et al. (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361(9354) 296-300... [Pg.276]

Decensi A, Maisonneuve P, Rotmenz N et al. (2005) Effect of Tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 111 650-656... [Pg.276]

Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al. (1994) Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343 1318-1321... [Pg.297]

Tait CR (2004) Aspirin and breast cancer prevention a link to ER status. Breast Cancer Res 6 211-212... [Pg.357]

From a clinical perspective, tamoxifen is still the first and only SERM worth mentioning from the first- and second-generation compounds. The pharmacology of tamoxifen has been reviewed extensively [142]. The NSABP-11 adjuvant trial and the Breast Cancer Prevention Trial (BCPT-1) are some of the milestones in the history of tamoxifen [141]. [Pg.55]

Garlic 2 3 61.21 million (38), Atherosclerosis, colon Breast cancer prevention. [Pg.9]

Teas, J. 1973. The dietary intake of Laminaria, a brown seaweed, and breast cancer prevention. Nutr. Cancer 4 217-222. [Pg.324]

In the Breast Cancer Prevention Trial (P-1), initiated by the National Surgical Adjuvant Breast and Bowel Project (NSABP) in 1992, more than 13 000 eligible women were randomized to tamoxifen 20 mg/day or placebo for 5 years (26). During 69 months of follow-up tamoxifen reduced the risk of both invasive and non-invasive cancer... [Pg.302]

Rastogi P, Vogel VG. Update on breast cancer prevention. Oncology (Huntingdon) 2003 17 799-805. [Pg.310]

Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D Aiuto G, Gulisano M, Gucciardo G, Del Turco MR, Pizzichetta MA, Conforti S, Bonanni B, Boyle P, Veronesi U. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005 111 650-6. [Pg.311]

Russo, J. and Russo, I.H. 1995. Hormonally induced differentiation A novel approach to breast cancer prevention. J. Cell Biochem. 22, 58-64. [Pg.92]

In a breast cancer prevention study in high-risk women, treatment with a daily dose of 20 mg of tamoxifen for a median duration of 55 months decreased the risk of invasive breast cancer by 49% and the risk of ER-positive breast cancer by 69% (Fisher et al., 1998). However, in... [Pg.314]

Stimulated by the need for an improved therapy for breast cancer, considerable efforts have been devoted to the synthesis of compounds that would exert pure antiestrogenic activity in the mammary gland and uterus. As mentioned above, while tamoxifen has beneficial effects on breast cancer, it clearly acts as an estrogen agonist in the endometrium, leading to an increased rate of endometrial carcinoma in women taking tamoxifen under chronic conditions. Moreover, it is most likely that a pure antiestrogen will have beneficial effects superior to those of tamoxifen in breast cancer prevention and treatment. [Pg.318]

Howe et al. (425) reviewed the potential of using COX-2 inhibitors for the treatment of breast cancer and suggested that there is good rationale to examine COX-2 inhibition for breast cancer prevention. Limited data are available in animal models of breast cancer however, Harris et al. (426) showed that celecoxib inhibited the tumor multiplicity by 86% and the incidence by 68%. [Pg.249]


See other pages where Breast cancer prevention is mentioned: [Pg.1306]    [Pg.143]    [Pg.70]    [Pg.264]    [Pg.273]    [Pg.273]    [Pg.348]    [Pg.350]    [Pg.41]    [Pg.301]    [Pg.303]    [Pg.304]    [Pg.711]    [Pg.3297]    [Pg.505]    [Pg.79]    [Pg.1658]    [Pg.1659]    [Pg.2324]    [Pg.2350]   
See also in sourсe #XX -- [ Pg.1305 , Pg.1306 ]

See also in sourсe #XX -- [ Pg.688 ]

See also in sourсe #XX -- [ Pg.340 ]

See also in sourсe #XX -- [ Pg.688 ]

See also in sourсe #XX -- [ Pg.2334 , Pg.2358 , Pg.2359 , Pg.2360 ]




SEARCH



Cancer prevention

© 2024 chempedia.info